Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: a real-world experience from a low-middle income country

被引:2
作者
Mehta, Pankti [1 ,2 ]
Lawrence, Able [1 ]
Gupta, Latika [1 ,3 ,5 ,6 ]
Misra, Durga P. [1 ]
Agarwal, Vikas [1 ]
Misra, Ramnath [1 ,4 ]
Aggarwal, Amita [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, India
[2] King George Med Univ, Dept Clin Immunol & Rheumatol, Lucknow, India
[3] Royal Wolverhampton Hosp NHS Trust, Dept Rheumatol, Wolverhampton WV10 0QP, England
[4] Kalinga Inst Med Sci, Dept Clin Immunol & Rheumatol, Bhubaneswar, India
[5] Univ Manchester, Ctr Musculoskeletal Res, Sch Biol Sci, Div Musculoskeletal & Dermatol Sci, Manchester, England
[6] Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Dept Rheumatol, Birmingham, England
关键词
Calcinosis; Cyclophosphamide; Dermatomyositis; Pamidronate; Rheumatology; PROGNOSTIC-FACTORS; CLINICAL-FEATURES; ONSET; ANTIBODIES; CHILDREN; ADULT;
D O I
10.1007/s00296-023-05377-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To study the prevalence and predictors of calcinosis in Juvenile Dermatomyositis (JDM). Medical records over 20 years at a tertiary care rheumatology center in Northern India were reviewed to identify patients with JDM and clinical details were recorded. The frequency of calcinosis, predictors, specific treatment, and its outcomes were studied. Data are expressed as median and interquartile range. In eighty-six patients (median age 10) of JDM, the frequency of calcinosis was 18.2% (8.5% at presentation). Younger age at presentation, longer follow-up, heliotrope rash [Odds Ratio (95% confidence interval), 11.4 (1.4-92.12)], chronic or polycyclic course [4.4 (1.2-15.5)] and cyclophosphamide use [8.2 (1.6-41.9)] were associated with calcinosis. Dysphagia [0.14 (0.02-1.2)] and elevated muscle enzymes [0.14 (0.04-0.5)] were negatively associated with calcinosis. Treatment with pamidronate had a good to moderate response to calcinosis in five of seven children. Calcinosis in JDM is associated with long-standing, poorly controlled disease, and the use of bisphosphonates like pamidronate offer promise in the future for its treatment.
引用
收藏
页码:3035 / 3040
页数:6
相关论文
共 20 条
[1]   The Clinical Features of Myositis-Associated Autoantibodies: a Review [J].
Gunawardena, Harsha .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 52 (01) :45-57
[2]   The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis [J].
Hoeltzel, Mark F. ;
Oberle, Edward J. ;
Robinson, Angela Byun ;
Agarwal, Arunima ;
Rider, Lisa G. .
CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (12) :1-11
[3]   2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups [J].
Lundberg, Ingrid E. ;
Tjarnlund, Anna ;
Bottai, Matteo ;
Werth, Victoria P. ;
Pilkington, Clarissa ;
de Visser, Marianne ;
Alfredsson, Lars ;
Amato, Anthony A. ;
Barohn, Richard J. ;
Liang, Matthew H. ;
Singh, Jasvinder A. ;
Aggarwal, Rohit ;
Arnardottir, Snjolaug ;
Chinoy, Hector ;
Cooper, Robert G. ;
Danko, Katalin ;
Dimachkie, Mazen M. ;
Feldman, Brian M. ;
Garcia-De La Torre, Ignacio ;
Gordon, Patrick ;
Hayashi, Taichi ;
Katz, James D. ;
Kohsaka, Hitoshi ;
Lachenbruch, Peter A. ;
Lang, Bianca A. ;
Li, Yuhui ;
Oddis, Chester V. ;
Olesinska, Marzena ;
Reed, Ann M. ;
Rutkowska-Sak, Lidia ;
Sanner, Helga ;
Selva-O'Callaghan, Albert ;
Song, Yeong-Wook ;
Vencovsky, Jiri ;
Ytterberg, Steven R. ;
Miller, Frederick W. ;
Rider, Lisa G. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) :1955-1964
[4]   Autoantibodies in myositis [J].
McHugh, Neil J. ;
Tansley, Sarah L. .
NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (05) :290-302
[5]   Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA) [J].
Orandi, A. B. ;
Baszis, K. W. ;
Dharnidharka, V. R. ;
Huber, A. M. ;
Hoeltzel, M. F. .
PEDIATRIC RHEUMATOLOGY, 2017, 15
[6]   Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity [J].
Pachman, Lauren M. ;
Khojah, Amer M. .
JOURNAL OF PEDIATRICS, 2018, 195 :16-27
[7]   Duration of illness is an important variable for untreated children with juvenile dermatomyositis [J].
Pachman, LM ;
Abbott, K ;
Sinacore, JM ;
Amoruso, L ;
Dyer, A ;
Lipton, R ;
Ilowite, N ;
Hom, C ;
Cawkwell, G ;
White, A ;
Rivas-Chacon, R ;
Kimura, Y ;
Ray, L ;
Ramsey-Goldman, R .
JOURNAL OF PEDIATRICS, 2006, 148 (02) :247-253
[8]  
Pachman LM., 2015, NEUROMUSCUL DISORD I
[9]   Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience [J].
Patwardhan, Anjali ;
Rennebohm, Robert ;
Dvorchik, Igor ;
Spencer, Charles H. .
PEDIATRIC RHEUMATOLOGY, 2012, 10
[10]   Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? [J].
Prasad, Shiva ;
Misra, Ramnath ;
Agarwal, Vikas ;
Lawrence, Able ;
Aggarwal, Amita .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2013, 16 (05) :556-560